GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Telix Pharmaceuticals TLX.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

13.93

+1.90%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$803.8m

FY2017FY2025

Net income

−$7.1m

FY2017FY2025

Free cash flow

−$73.3m

FY2017FY2025

Shareholders' equity

$415.4m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$803.8m$516.6m$333.0m$103.8m$7.6m$5.2m$3.5m$195,100—
Research and development$171.2m$127.9m$85.3m$52.5m$34.1m$23.1m$21.2m$18.7m$3.0m
Operating income$30.9m$54.6m$12.3m−$58.9m−$76.9m−$35.6m−$28.4m−$17.5m−$6.2m
Net income−$7.1m$33.7m$4.2m−$67.5m−$80.5m−$44.9m−$27.9m−$13.8m−$6.4m
Diluted earnings per share-0.020.100.01-0.22-0.29-0.17-0.12-0.07-0.05

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$1.16bn$940.4m$277.3m$165.6m$109.8m$157.8m$102.6m$76.7m$51.1m
Cash and short-term investments$141.9m$440.0m$84.3m$75.4m$22.0m$77.9m$44.6m$25.8m$48.8m
Total liabilities$748.6m$587.4m$174.6m$113.7m$107.7m$78.8m$32.5m$23.8m$1.8m
Debt$467.1m$360.2m$12.3m$6.8m$2.5m$2.2m$2.1m$1.7m$345,400
Shareholders' equity$415.4m$352.9m$102.6m$51.9m$2.2m$79.0m$70.1m$52.9m$49.3m
Shares outstanding338m345m324m311m282m257m233m202m128m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$17.3m$27.5m$14.3m−$41.5m−$59.3m$2.0m−$23.3m−$20.7m−$6.0m
Capital spending−$56.0m−$30.6m−$7.1m−$9.0m−$1.3m−$322,000−$468,000—−$5,600
Free cash flow−$73.3m−$3.1m$7.2m−$50.5m−$60.7m$1.6m−$23.8m−$20.7m−$6.0m

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023Dec 2022
Revenue$413.4m$390.4m$276.9m$239.6m$281.7m$220.8m$110.4m$136.0m
Operating income$21.7m$9.2m$21.8m$32.8m$22.7m−$5.1m$15.6m−$21.6m
Net income−$4.8m−$2.3m$14.1m$19.6m$19.5m−$14.3m−$7.2m−$33.2m
Diluted earnings per share-0.01-0.010.040.060.06-0.05-0.02-0.11
Cash from operations−$35.0m$17.0m$4.0m$23.0m$10.0m$13.0m—−$3.0m
Capital spending−$27.0m−$28.0m−$17.0m−$13.0m−$7.0m−$3.0m—−$4.0m
Free cash flow−$62.0m−$11.0m−$13.0m$10.0m$3.0m$10.0m—−$7.0m
Total assets$1.16bn$1.19bn$940.4m$483.8m$406.0m$310.3m$310.3m$255.4m
Cash and short-term investments$141.9m$207.2m$440.0m$77.1m$123.2m$131.7m$131.7m$116.3m
Debt$448.4m$397.2m$346.9m$11.9m$15.9m$12.3m$12.3m$9.8m
Shareholders' equity$415.4m$421.9m$352.9m$262.0m$148.9m$76.1m$76.1m$80.0m

Financial ratios

Data as of 24 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin2.2%10.5%3.2%-61.3%-990.6%-1133.3%
Net margin-0.9%6.4%1.0%-65.0%-1059.9%-861.1%
Return on equity-1.8%8.8%3.5%-130.1%-3730.8%-56.8%
Return on assets-0.6%3.3%1.3%-40.8%-73.3%-28.4%
Free cash flow yield0.7%1.7%0.8%-1.2%-1.6%0.1%
Revenue growth59.2%55.8%213.9%2007.6%45.7%49.6%
Earnings growth-122.1%858.0%-105.0%29.3%79.4%61.1%
Current ratio1.43x2.78x1.48x2.02x1.25x4.69x
Debt to equity0.67x1.01x0.07x0.05x0.29x0.01x
Equity ratio35.1%37.5%36.3%31.3%2.0%50.1%
Interest coverage0.48x3.82x16.26x-241.91x-398.13x-50.28x
R&D as a share of sales21.3%24.9%25.6%36.1%449.4%442.8%
Buybacks as a share of market value1.9%-6.6%-2.3%-11.8%-8.9%-6.8%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue97.8%173.9%—
Net income-52.7%-30.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-385.1182.8—-24.3-19.7-15.7
Price to sales3.411.97.115.8208.8135.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.